Immunovant (IMVT) 424B324 Jan 25Prospectus supplementFinancial data

Company Profile

Offerings - Offering: 1	Jan. 24, 2025 USD ($) shares
Offering:
Fee Previously Paid	false
Rule 457(r)	true
Security Type	Equity
Security Class Title	Common Stock, par value $0.0001 per share
Amount Registered \| shares	5,654,990
Proposed Maximum Offering Price per Unit	23.65
Maximum Aggregate Offering Price	$ 133,740,513.5
Fee Rate	0.01531%
Amount of Registration Fee	$ 20,475.68
Offering Note	(1) Represents shares offered by the selling stockholders identified in this prospectus supplement. Includes an indeterminate number of additional shares of common stock that, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), may be issued to prevent dilution from stock splits, stock dividends or similar transactions that could affect the shares to be offered by the selling stockholders. (2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based upon the average of the high and low prices of the common stock on the Nasdaq Global Select Market on January 22, 2025. (3) Pursuant to Rule 415(a)(6) under the Securities Act, the Registrant filed the Registration Statement on Form S-3ASR No. 333-275419) S-3 No. 333-251865), “at-the-market”

Offsets	Jan. 24, 2025 USD ($)
Offset: 1
Offset Payment:
Offset Claimed	true
Rule 457(p) Offset	true
Registrant or Filer Name	Immunovant, Inc.
Form or Filing Type	S-3
File Number	333-251865
Initial Filing Date	Jan. 04, 2021
Fee Offset Claimed	$ 54,870.15
Security Type Associated with Fee Offset Claimed	Unallocated (Universal) Shelf
Security Title Associated with Fee Offset Claimed	Unallocated (Universal) Shelf
Unsold Aggregate Offering Amount Associated with Fee Offset Claimed	$ 455,950,066
Offset Note	(3) Pursuant to Rule 415(a)(6) under the Securities Act, the Registrant filed the Registration Statement on Form S-3ASR No. 333-275419) S-3 No. 333-251865), “at-the-market”
Termination / Withdrawal Statement	the offering of the Unsold Securities registered under the Prior Registration Statement was deemed terminated as of November 9, 2023.
Offset: 2
Offset Payment:
Offset Claimed	false
Rule 457(p) Offset	true
Registrant or Filer Name	Immunovant, Inc.
Form or Filing Type	S-3
File Number	333-251865
Filing Date	Jan. 04, 2021
Fee Paid with Fee Offset Source	$ 54,870.15
Offset Note	(3) Pursuant to Rule 415(a)(6) under the Securities Act, the Registrant filed the Registration Statement on Form S-3ASR No. 333-275419) S-3 No. 333-251865), “at-the-market”